A small Japanese trial implied the superiority of selective HCT (in which CD34 + cells are chosen for infusion) to the non-selective process (32), van Bijnen et al. reported similar positive results to ASTIS (1), and Henrique-Neto et al. (33) were also in line with these findings supporting HCT as a viable therapeutic choice for severe systemic sclerosis. Here, CD34 is linked to systemic sclerosis.